• FDA Approves Dacomitinib for Metastatic Non-Small Cell Lung Cancer americanpharmaceuticalreview
    September 29, 2018
    The Food and Drug Administration (FDA) has approved dacomitinib tablets (VIZIMPRO, Pfizer Pharmaceutical Company) for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon
PharmaSources Customer Service